Embryo implantation involves a complex regulatory network of steroid hormones, inflammatory cytokines, and immune cells. Lipoxin A 4 (LXA 4 ), a biologically active eicosanoid with specific anti-inflammatory and pro-resolving properties, was recently found to be a novel modulator of estrogen receptor a (ERa). In this study, we investigated the potential role of LXA 4 in implantation. We found that LXA 4 blocked embryo implantation in mice and significantly reduced the expression of inflammatory mediators associated with uterine receptivity and embryo implantation, including corticotropin-releasing factor (CRF), cyclooxygenase 2-derived prostaglandin I 2 and prostaglandin E 2 , leukemia inhibitory factor, and interleukin 6, but this effect was independent of LXA 4 receptor. Subsequent investigation revealed enhanced ERa activity in the uteri of LXA 4 -treated mice during the peri-implantation period. ERa and phosphorylated ERa were significantly increased following LXA 4 treatment. Finally, it was demonstrated that the inhibitory effect of LXA 4 on embryo implantation was mediated through ERa. In the presence of the ERa antagonist ICI 182 780, LXA 4 failed to block embryo implantation. LXA 4 also failed to inhibit CRF expression. These results suggested that LXA 4 blocks embryo implantation by controlling ERa activity, and this effect appeared to be related to the suppression of the inflammatory microenvironment necessary for implantation.
Introduction
Embryo implantation is a crucial step in mammalian reproduction. It can only take place during a very specific time, commonly known as the window of implantation. During this period the uterus undergoes a sequence of cellular and molecular events in the endometrium and differentiates to provide a specialized environment for the incoming embryo (Paria et al. 2002) . Hormones play central roles in the regulation of uterine environment. The principal hormones that specify uterine receptivity are ovarian steroids estrogen and progesterone (Wang & Dey 2006) . Estrogen is essential for an integrated uterine response, and estrogen signaling is primarily mediated through estrogen receptor (ER), ERa and ERb. ERa is dominantly expressed within the uterus, and studies on knockout mice models have revealed that ERa, but not ERb, is necessary for normal fertility (Paria et al. 2002 , Wang & Dey 2006 . However, estrogen activity must be tightly controlled during the peri-implantation period. Estrogen at a low level extends the window of uterine receptivity for implantation, but excessive high estrogen levels can prematurely close this window, transforming the uterus into a refractory state (Ma et al. 2003) .
Although decidual development is governed by the ovarian steroid hormones, there is increasing evidence for the local immune regulation. Inflammatory microenvironment is closely related to endometrial remodeling during implantation. The fetal-maternal interface is rich in inflammatory cytokines (Jones et al. 2004 ) and dynamically populated with a wide variety of innate immune cells (Hanna et al. 2006 , Plaks et al. 2008 . One of the mediators that play important roles in the aseptic inflammatory process of implantation is corticotropin-releasing factor (CRF). CRF, a hypothalamic neuropeptide that modulates the activity of the hypothalamus-pituitary-adrenal axis, is also secreted in peripheral tissues and possesses potent pro-inflammatory properties (Theoharides et al. 1998 , Venihaki et al. 2001 , Cao et al. 2005 . CRF is produced in several organs of the female reproductive system, including endometrial glands, decidualized stroma, and trophoblast (Mastorakos et al. 1996 , Zoumakis et al. 2000 . Locally produced CRF might stimulate the expression of FasL, thereby potentiating their ability to induce apoptosis of surrounding activated T lymphocytes (Makrigiannakis et al. 2001) . Cyclooxygenase 2 (COX2)-derived prostaglandins (PGs) are also important inflammatory mediators in implantation (Lim et al. 1999 , Pakrasi & Jain 2008 . PGs contribute to successful implantation via their effects on decidual angiogenesis, and Ptgs2-deficient mice show multiple reproductive failures, including defective decidualization and impaired implantation (Lim et al. 1997) . Pro-inflammatory cytokines, such as leukemia inhibitory factor (LIF), interleukin 6 (IL6), IL8, and monocyte chemotactic protein 1 (MCP1), are also involved in the inflammatory response in implantation (Dominguez et al. 2005 , van Mourik et al. 2009 ). Among the cytokine family, LIF is most pertinent to implantation. Gene targeting studies have showed the essential role of LIF in uterine preparation for implantation (Stewart et al. 1992) . Implantation involves a complex regulatory network of steroid hormones, inflammatory cytokines, and immune cells as described earlier. However, how they interact and how they are coordinated are not clearly understood.
Lipoxins (LXs), which are derived from arachidonic acid in the context of inflammation, are the first recognized pro-resolving lipid mediators and are thought to be the 'stop signal' for inflammation. LXs have been extensively studied for their anti-inflammatory or pro-resolving effects (Serhan & Savill 2005 , Serhan et al. 2008 . Recently, our group revealed some new properties of LXs, including the regulatory mechanism in tumor immunoediting . As discussed earlier, there is a close relationship between implantation and inflammation. So we are interested in the potential role of LXs in embryo implantation (Xiong et al. 2011) . Moreover, a recent study described lipoxin A 4 (LXA 4 ) with estrogenic activity (Russell et al. 2011) . This raises the question of whether estrogen signaling is involved in the effect of LXs on embryo implantation?
In this study, we investigated the effect of LXA 4 on embryo implantation, focusing on its influence on estrogen signaling and inflammatory mediators associated with uterine receptivity and embryo implantation. Our results showed that LXA 4 blocks embryo implantation by controlling ERa activity, and this effect appeared to be related to the suppression of inflammatory microenvironment necessary for implantation.
Results

LXA 4 blocks embryo implantation
LXA 4 was administered as described earlier. All control mice displayed implantation sites (meanGS.E.M., 12.8 G1.7). However, none of the ten mice that received LXA 4 showed any implantation sites (Fig. 1) . The pregnancy status of the mice without implantation sites was determined by flushing their reproductive tract for the presence of embryos. All mice treated with LXA 4 had no detectable implantation sites but embryos flushed from the uterus. Therefore, this study focused on the effect of LXA 4 on the uterus, specifically uterine receptivity for embryo implantation.
LXA 4 adversely affects uterine receptivity for embryo implantation
An embryo transfer study was further performed to evaluate the effect of LXA 4 on uterine receptivity. All control mice with successful embryo transfer had implantation sites. There were 107 visible implantation sites, resulting from 200 embryos transferred (53.5%). However, none of the LXA 4 -treated mice with successful embryo transfer had any detectable implantation sites ( Fig. 2A, and B) . Furthermore, histological examination of these transferred blastocysts and consequent implantation sites was performed to determine whether embryos properly attach to the uterine lumen. Successful attachment and invasion into uterine stroma of the embryos was observed in all controls. Moreover, the stromal bed surrounding these embryos underwent a decidual response. However, in LXA 4 -treated mice, embryos failed to attach to the uterine luminal epithelium. An interesting observation was that the uteri showed an initial response to decidualization. However, the stromal bed showed poor vascular permeability resulting from reduced edema ( Fig. 2C and D) . Therefore, LXA 4 adversely affects uterine receptivity for embryo implantation.
LXA 4 influences uterine development during implantation
The above observations led us to examine uterine histology in LXA 4 -treated mice. During implantation, the uterus undergoes a sequence of cellular and molecular events and differentiates into a state of receptivity. Cellular changes include the development of secretory glands, the emergence of large apical protrusions on the luminal epithelium (pinopodes), as well as the transformation of fibroblast-like stromal cells into large and rounded decidual cells (decidualization) (Paria et al. 2002) . Histological examination of the uteri of the control mice showed normal morphological appearance. Secretion from luminal epithelium or endometrial glands and stromal decidualization were observed. However, in LXA 4 -treated mice, these changes did not obvious. Increased endometrial vascular permeability at the implantation sites is also a key event in implantation (Wang & Dey 2006) . However, the uterine stroma of LXA 4 -treated mice showed poor vascular permeability with reduced extent of edema (Fig. 3) .
LXA 4 reduces the expression of inflammatory mediators associated with uterine receptivity and embryo implantation Inflammatory microenvironment is closely related to endometrial remodeling during implantation; we we performed quantitative real-time RT-PCR analysis and ELISA assay. These data confirmed the immunohistochemistry result. CRF expression was significantly reduced at both mRNA and protein levels in LXA 4 -treated mice compared with controls ( Fig. 4C, and D) . As COX2-derived PGs are also important inflammatory mediators in implantation (Lim et al. 1999 , Pakrasi & Jain 2008 , we further examined whether LXA 4 treatment could reduce COX2 expression and consequently inhibit the production of PGs during implantation. We found that the uterine expression of COX2 was significantly decreased in LXA 4 -treated mice compared with the control mice (Fig. 4E) . The levels of PGI 2 and PGE 2 , the most abundant PGs at implantation sites, were also significantly lower in LXA 4 -treated mice than in the control mice (Fig. 4F) .
Pro-inflammatory cytokines, such as LIF, IL6, IL8, and MCP1, are also involved in the inflammatory response in implantation (Dominguez et al. 2005 , van Mourik et al. 2009 ). To further confirm the inhibitory effect of LXA 4 on inflammatory microenvironment required for implantation and ascertain the possible inflammatory pathways involved, we examined whether LXA 4 treatment could also reduce the levels of these pro-inflammatory cytokines during implantation. It was also found that LXA 4 treatment significantly suppressed the expression of LIF and IL6. Similar trends were also observed for IL8 a nd MCP1, although the difference did not reach statistical significance ( Fig. 4G and H) .
LXA 4 receptor is dispensable for the inhibitory effect of LXA 4 on embryo implantation Biological actions of LXA 4 are mediated through several mechanisms. These include activation of LX-specific receptor (ALX), interaction with a subclass of cysteinylleukotriene receptors (CysLTs), as well as the nuclear receptor aryl hydrocarbon receptor (AhR; Chiang et al. 2006 , Maderna & Godson 2009 ). LXA4 exerts antiinflammatory and pro-resolving effects specifically via ALX (Chiang et al. 2006 , Ye et al. 2009 ). ALX has been identified in diverse cells and tissues, including endometrium (Motohashi et al. 2005 , Macdonald et al. 2011 . To determine the role of ALX in the observed inhibitory effect of LXA 4 on embryo implantation, additional experiment was performed in which the mice were pretreated with the formyl peptide receptor 2 (FPR2)/ALX antagonist N-t-butoxycarbonyl-Phe-LeuPhe-Leu-Phe (Boc2). Interestingly, Boc2 did not reverse the inhibitory effect of LXA 4 on embryo implantation (Fig. 5A, B , C, D, and E). Furthermore, Boc2 did not alter the inhibitory effect of LXA 4 on CRF expression (Fig. 5F ). ERa activity is enhanced in the uteri of LXA 4 -treated mice
Uterine functions are primarily directed by estrogen and progesterone, and their actions are largely mediated through ERa and progesterone receptor (PR) respectively. We then investigated the influence of LXA 4 on estrogen and progesterone signaling during implantation. We observed that serum levels of E 2 and P 4 in LXA 4 -treated mice on day 5 were similar to those in the control mice (Fig. 6A, and B) and that LXA 4 -treated mice had a normal expression pattern of PR (Fig. 6D , E, J, and K). However, uterine ERa expression was altered. As shown in Fig. 6C , ERa expression was significantly increased in LXA 4 -treated mice compared with controls by qRT-PCR. This result was further confirmed by western blotting and immunohistochemical staining (Fig. 6E , H, and I). It is well known that ERa activation involves ERa phosphorylation at specific sites. A major site of phosphorylation is located at serine 122 in mouse, corresponding to serine 118 of the human protein (Kato et al. 1995 , Nilsson et al. 2001 . To further determine whether these receptors are activated or not, we examined the phosphorylation status of ERa. Accordingly, the phosphorylation of ERa at serine 122 was significantly increased following LXA 4 treatment (Fig. 6E, F, and G) . Collectively, these data showed a considerable increase in ERa expression and activation in the uteri of LXA 4 -treated mice, implicating involvement of ERa in the inhibitory mechanism of LXA 4 in embryo implantation.
ERa is involved in the inhibitory mechanism of LXA 4 in embryo implantation
Mice treated with LXA 4 exhibited implantation failure and enhanced ERa activity, suggesting that ERa might be involved in the inhibitory mechanism of LXA 4 in embryo implantation. To determine whether enhanced ERa activity is the prime cause of defective implantation, we assessed whether inhibition of ERa activity could rescue LXA 4 -induced implantation defect. ICI 182 780 (ICI) a pure ERa antagonist, was used to inhibit ERa activity during the receptive period. ICI, at the dose given here, had little effect on implantation. As expected, LXA 4 -treated mice failed to display embryo implantation, consistent with our previous observation. In contrast, in the presence of ICI, LXA 4 failed to block embryo implantation (Fig. 7A, B , C, D, and E). LXA 4 also failed to inhibit CRF expression (Fig. 7F ). These results demonstrate that LXA 4 blocks embryo implantation through controlling ERa activity.
Discussion
Synchronizing uterine differentiation with embryonic development is crucial to successful implantation. Estrogen is essential for preparation of the progesterone-primed uterus to the receptive state and has been shown to be a critical determinant that specifies the duration of the window of uterine receptivity for implantation. Estrogen at a low level extends the window of uterine receptivity, but excessively high estrogen levels can prematurely close this window, transforming the uterus into a refractory state. The uterine refractoriness at high estrogen levels is accompanied by aberrant expression of implantation-related genes (Ma et al. 2003) . Thus, estrogen activity must be tightly controlled during the peri-implantation period. Disrupting estrogen activity is the basis of the estrogen-containing 'morning after pill' (Grimes & Raymond 2002) . LXA 4 has been implicated in uterine physiology. The enzymes necessary for LXs biosynthesis and metabolism have previously been described in the endometrium (Lousse et al. 2010) . Significantly higher expression of ALX is also detected in the endometrium (Motohashi et al. 2005) . More importantly, the anti-inflammatory action of LXA 4 observed in the endometrium (Macdonald et al. 2011) suggests a potential role of LXA 4 signaling in the regulation of inflammatory events associated with endometrial remodeling during embryo implantation. Recently, LXA 4 is confirmed to be a novel ER modulator. Russell et al. (2011) showed that LXA 4 competes with E 2 for ER binding and possesses a dual capacity to alter estrogen response element transcriptional activity, and alkaline phosphatase activity, as well as expression of estrogen-regulated genes in human endometrial cells. Therefore, it will be of considerable interest to study the potential role of LXA 4 in embryo implantation. Here, we demonstrated that the estrogenic activity of LXA 4 is involved in contraceptive events. Our data showed that LXA 4 blocks embryo implantation by interference with the local inflammatory microenvironment necessary for implantation, and that this inhibitory effect of LXA 4 is mediated through ERa.
Although the embryonic effect of LXA 4 is not directly tested, we demonstrated a potent effect of LXA 4 on uterine receptivity. We observed that preimplantation treatment of LXA 4 resulted in implantation failure. None of the ten mice that received LXA 4 showed any implantation sites. First, as ovulation and fertilization happen during the dark cycle before 0500 h on gestation day 1 (Nagy et al. 2003) , the LXA 4 treatment regimen in this study, which started at 0900 -1000 h of gestation day 1, should not affect the ovulation and fertilization processes. Secondly, all mice treated with LXA 4 had no detectable implantation sites but embryos flushed from the uterus only, suggesting no effect of LXA 4 on embryo transport in the reproductive tract. Therefore, failed implantation following LXA 4 treatment might result from compromised uterine receptivity, which was subsequently confirmed by the embryo transfer study. To exclude any possible influence of LXA 4 on the embryo, we transferred embryos to LXA 4 -treated pseudopregnant mice. These embryotransferred mice also showed implantation failure. None of LXA 4 -treated mice with successful embryo transfer had any detectable implantation sites. These results suggested that LXA4 blocks embryo implantation by altering uterine receptivity.
Inflammatory microenvironment is closely related to endometrial remodeling during embryo implantation. We therefore asked whether the inhibitory effect of LXA 4 on embryo implantation and uterine receptivity is associated with the change in the local inflammatory microenvironment in the endometrium. CRF, COX2-derived PGs, and pro-inflammatory cytokines including LIF, IL6, IL8, and MCP1 are important inflammatory mediators in implantation (Lim et al. 1999 , Makrigiannakis et al. 2001 , Dominguez et al. 2005 , Pakrasi & Jain 2008 , van Mourik et al. 2009 ). So these inflammatory mediators were chosen as our primary research targets. We observed that LXA 4 treatment significantly reduced the expression levels of CRF, COX2, PGI 2 , PGE 2 , LIF, and IL6. Similar trends were also observed with respect to IL8 and MCP1 expression, although the difference did not reach statistical significance. These results confirmed that LXA 4 might hinder the local inflammatory microenvironment during implantation.
Biological actions of LXA 4 are mediated through various receptors, including ALX, and CysLTs, as well as AhR (Chiang et al. 2006 , Maderna & Godson 2009 . ALX is the first receptor cloned and identified as a G-proteincoupled receptor for lipoxygenase-derived eicosanoids with demonstrated cell-type-specific signaling pathways (Chiang et al. 2006) . LXA 4 exhibits high-affinity binding with ALX, and the LXA 4 -ALX axis is responsible for the anti-inflammatory and pro-resolving signals (Chiang et al. 2006 , Ye et al. 2009 ). ALX is expressed in diverse cells and tissues, including endometrium (Motohashi et al. 2005 , Macdonald et al. 2011 . However, we observed that ALX is dispensable for the inhibitory effect of LXA 4 on embryo implantation. Boc2 did not reverse the inhibitory effect of LXA 4 on embryo implantation and CRF expression. Subsequent observation suggested that ERa is involved in the inhibitory mechanism of LXA 4 in embryo implantation. In the presence of ICI, LXA 4 failed to block embryo implantation. LXA 4 also failed to inhibit CRF expression. Therefore, the role of LXA 4 in implantation is not simply through anti-inflammatory and pro-resolving effects but also via the regulatory mechanisms involved in the endocrine-immune cross talk.
It is worth noting that the mice with LXA 4 treatment exhibited enhanced ERa activity in endometrium during embryo implantation. This is in contrast to the antiestrogenic action of LXA 4 observed in human endometrial epithelial cells in vitro (Russell et al. 2011) . One reason for the different findings may be the relative concentrations of LXA 4 and E 2 . The overall response is governed by complex interactions between LXA 4 , E 2 , and ER. Another possible reason is the in vivo cellular context. Stromal cells play a significant role in implantation (Franco et al. 2011 , Shuya et al. 2011 Das et al. 2012) and may respond differently to LXA 4 compared with epithelial cells. We have also observed increased ERa expression in LXA 4 -treated mice. The uterine response to estrogen is primarily mediated through ER, whose expression in turn is regulated by estrogen. Previous studies revealed that the expression of ERa varies during the estrous cycle and peaks during proestrous in accordance with the circulating E 2 levels, indicating that uterine ERa is specifically induced by endogenous estrogen (Winuthayanon et al. 2010) . Therefore, this finding further confirmed the estrogenic activity of LXA 4 in vivo.
Additionally, to exclude the possible interference of endogenous estrogen, we also analyzed the serum levels of E 2 . LXA 4 does not affect the serum E 2 levels. Thus, it can be speculated that LXA 4 does not disturb ovarian secretion.
In conclusion, this study first proposes the LXA 4 /ERa axis existed in the endometrium during implantation and indicates that dysregulation of ERa activity by LXA 4 could be a promising female contraceptive. LXA 4 does not disturb ovarian secretion. What is more, LXA 4 is rapidly converted to biologically inactive lipid in vivo (Gilroy et al. 2004) , so it is easy to restore reproductive function. Our results help to enrich functional properties of LXA 4 and provide novel insights into the endocrineimmune cross talk mechanisms during implantation.
Materials and Methods
Reagents and antibodies
LXA 4 (5S, 6R, 15S-trihydroxy-7E, 9E, 11Z, 13E-eicosatetraenoic acid) was obtained from Cayman Chemical Company (Ann Arbor, MI, USA). Boc2 (N-t-butyloxycarbonyl-Phe-Leu-PheLeu-Phe), an antagonist of FPR2/ALX, was purchased from GenScript (Piscataway, NJ, USA). ICI 182 780, a pure ER antagonist, was purchased from Sigma-Aldrich. Reagents were dissolved in ethanol or DMSO and further diluted in PBS on the day of administration. Equivalent concentrations of ethanol or DMSO were used as vehicle controls. Affinity-purified goat polyclonal antibody CRF (C-20) (sc-1759), rabbit polyclonal antibody ERa (MC-20) (sc-542), rabbit polyclonal antibody phosphorylated ERa (Ser 122) (sc-101675), and rabbit polyclonal antibody PR (C-19) (sc-538) were from Santa Cruz Biotechnology.
Animal study protocol
The study was approved by the Animal Care and Use Committee of Huazhong University of Science and Technology (S230). Experiments involving mice (Kunming White outbred strain) used animals obtained from the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology. The mice were maintained in a controlled environment with a 14 h light:10 h darkness cycle. All animals appeared healthy throughout the experiments.
Female mice (8 weeks old) were naturally mated with fertile males of the same strain. The presence of a vaginal plug after mating was designated as day 1 of pregnancy. Pregnant mice were randomly allocated to two groups, with ten animals per group. Group A received placebo vehicle and group B received LXA 4 (10 mg/kg i.p.). Injections were done on days 1-3. The implantation sites on day 5 were identified by i.v. injection of 0.1 ml 1% Chicago blue (Sigma-Aldrich), and the number of implantation sites was recorded. If no implantation sites were detected, the uterine horns were flushed with PBS to determine the presence of embryos. The uteri were collected and placed in 4% buffered formalin overnight for morphological study or stored at K80 8C until ready for gene expression analysis.
The embryo transfer technique has been previously described (Nagy et al. 2003) . Briefly, 8-week-old female mice were superovulated with i.p. injections of 5 IU equine chorionic gonadotropin (Sigma-Aldrich) and 48 h later with 5 IU human chorionic gonadotropin (Sigma-Aldrich) and subsequently mated with fertile males. Meanwhile, pseudopregnant females were prepared by mating with vasectomized males. The following day was designated as gestation day 1 when a vaginal plug was identified. The pseudopregnant females were given daily injections of placebo vehicle or 10 mg/kg LXA 4 (10/group) on days 1-3. On day 4, blastocysts were harvested from superovulated females and transferred into the uteri of pseudopregnant females (10/horn). Resultant implantation sites were detected by blue dye injection on day 5. Histological examination of these transferred blastocysts and consequent implantation sites was performed to determine whether embryos properly attach to the uterine lumen.
To assess whether the effect of LXA 4 on embryo implantation is mediated through ALX or ERa, additional experiments were performed in which the mice were pretreated with the FPR2/ALX antagonist Boc2 (10 mg/kg) or the ERa antagonist ICI (250 ng/kg) respectively. All these agents have been used at doses previously shown to produce the desired pharmacological effects (von der Weid et al. 2004 , Lee et al. 2010 . Thirty minutes after administration of one of these drugs, LXA 4 was given as stated earlier. Embryo implantation was assessed on day 5 of pregnancy, and uterine tissues were processed for further analysis.
Morphological analysis
Embryo implantation at day 5 of pregnancy was assessed macroscopically by i.v. injection of Chicago blue dye, and the implantation sites were visualized as distinct blue bands. For histological assessment, the isolated uterine samples were fixed overnight in 4% buffered formalin and processed for routine H&E staining. Immunohistochemical staining was performed by EnVision method. The expression of CRF, ERa, phosphorylated ERa, and PR were detected by anti-CRF (1:200), anti-ERa (1:200), anti-pERa (1:200), or anti-PR (1:200) primary antibody respectively. Control samples were run accordingly. As a negative control, non-immune serum was substituted for the primary antibody.
Quantitative real-time PCR
Total RNAs from uterine tissues were isolated using Trizol reagent (Invitrogen) and reverse transcribed into cDNA with M-MLV (Invitrogen). qPCR analysis was performed with SYBR Green qPCR kit (Roche) on Stratagene Mx3000 Quantitative PCR System (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The sets of primer sequences used in this study were as follows: CRF forward 5 0 -ATGCTG-CTGGTGGCTCTGT-3 0 and reverse 5 0 -GCTCCGGCTGCAA-GAA-3 0 ; COX2 forward 5 0 -CACCTCTGCGATGCTCTTCC-3 0 and reverse 5 0 -CTGGTCAAATCCTGTGCTCATAC-3 0 ; LIF forward 5 0 -TTCCCATCACCCCTGTAAATG-3 0 and reverse 5 0 -CA-CCTGTGCCATACGCCACCCA-3 0 ; ERa forward 5 0 -GATGA-AAGGCGGCATACGG-3 0 and reverse 5 0 -CAGGGCTATTCT-TCTTAGTGTGC-3 0 ; PR forward 5 0 -CCAGATTCAGAAGCCA-GAA-3 0 and reverse 5 0 -CTCCCACAGGTAAGCAC-GC-3 0 . The expression of target genes was normalized to that of GAPDH.
Western blotting
Proteins were extracted from uteri in the lysis buffer (50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.2 mM sodium vanadate, 1% phenylmethylsulfonyl fluoride, and 0.2% aprotinin). Protein concentration was measured by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). The protein extracts were resolved by SDS-PAGE and subsequently transferred to nitrocellulose membranes. Immunodetection was performed by standard procedures. After being blocked in 5% nonfat milk in TBST for 1 h, the membranes were incubated with primary rabbit antiERa (1:200), anti-pERa (1:200), or anti-PR (1:200) overnight at 4 8C. The membranes were then washed three times in TBST and incubated with HRP-conjugated anti-rabbit secondary antibody (1:1000), followed by washing in TBST. The signals were developed with an ECL Kit (Millipore, Bedford, MA, USA). b-Actin served as an internal control.
ELISA
Levels of CRF, PGI 2 , PGE 2 , IL6, IL8, and MCP1 in the uterine extracts were quantified using respective ELISA kits as instructed by the manufacturer (R&D Systems, Minneapolis, MN, USA).
RIA
Serum was separated and serum levels of E 2 and P 4 were measured by RIA.
Statistical analysis
All data were presented as meanGS.E.M. Relative gene expression data were analyzed using the 2 KDDCT method (Livak & Schmittgen 2001) . Statistical significance for differences between groups was determined by Student's t-test or by oneway ANOVA. The significance level was set at P!0.05.
Declaration of interest
